In the NCI-MATCH trial, which included patients with NF1-, GNAQ-, or GNA11- mutant tumors, three patients with NF1-mutated NSCLC were initially enrolled, but only one was evaluable for response, showing a near-complete response. The gene discussed is NF1; the disease is non-small cell lung carcinoma.